AI Article Synopsis
- Lung cancer treatment has evolved significantly due to new discoveries in cancer biology, focusing on key targets like the c-MET/HGF axis.
- Changes in the c-MET gene and the levels of MET and HGF affect lung cancer outcomes and can make patients resistant to EGFR inhibitors, especially in those with non-small cell lung cancer (NSCLC).
- Ongoing research includes anti-MET and anti-HGF treatments, such as the monoclonal antibody Ficlatuzumab, which is being tested for its effectiveness in NSCLC patients.
Article Abstract
Lung cancer treatment has rapidly changed in the last few years thanks to novel insights into cancer biology. Several biomarkers and signaling pathways have been recognized as conceivable targets for treatment, and among them is the mesenchymal-epithelial transition/hepatocyte growth factor (c-MET/HGF) axis. Alterations in the c-MET gene and aberrations of MET and HGF expression impact on lung cancer prognosis and are involved in resistance to epidermal growth factor receptor (EGFR) inhibitors in non-small cell lung cancer (NSCLC) patients harboring activating EGFR mutations. Several anti-MET and anti-HGF strategies are currently under investigation, including monoclonal antibodies. Ficlatuzumab is a monoclonal antibody directed against HGF that is currently under investigation in NSCLC. The aim of the present review is to critically review available data on HGF and ficlatuzumab in NSCLC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3593708 | PMC |
| http://dx.doi.org/10.2147/BTT.S28908 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!